Cargando…

Strategies for Dodging the Obstacles in CAR T Cell Therapy

Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphom...

Descripción completa

Detalles Bibliográficos
Autores principales: Safarzadeh Kozani, Pooria, Safarzadeh Kozani, Pouya, Rahbarizadeh, Fatemeh, Khoshtinat Nikkhoi, Shahryar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047470/
https://www.ncbi.nlm.nih.gov/pubmed/33869011
http://dx.doi.org/10.3389/fonc.2021.627549
_version_ 1783679045750226944
author Safarzadeh Kozani, Pooria
Safarzadeh Kozani, Pouya
Rahbarizadeh, Fatemeh
Khoshtinat Nikkhoi, Shahryar
author_facet Safarzadeh Kozani, Pooria
Safarzadeh Kozani, Pouya
Rahbarizadeh, Fatemeh
Khoshtinat Nikkhoi, Shahryar
author_sort Safarzadeh Kozani, Pooria
collection PubMed
description Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. However, CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings. Adverse events such as cytokine release syndrome (CRS), neurotoxicity, graft rejection, on-target off-tumor toxicities, and tumor relapse have tied the rescuing hands of CAR T cell therapies. Moreover, in the case of solid tumor treatment, CAR T cell therapies have not yielded encouraging results mainly due to challenges such as the formidable network of the tumor microenvironments (TME) that operates in a suppressive fashion resulting in CAR T cell dysfunction. In this review, we tend to shine a light on emerging strategies and solutions for addressing the mentioned barriers. These solutions might dramatically help shorten the gap between a successful clinical outcome and the hope for it.
format Online
Article
Text
id pubmed-8047470
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80474702021-04-16 Strategies for Dodging the Obstacles in CAR T Cell Therapy Safarzadeh Kozani, Pooria Safarzadeh Kozani, Pouya Rahbarizadeh, Fatemeh Khoshtinat Nikkhoi, Shahryar Front Oncol Oncology Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. However, CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings. Adverse events such as cytokine release syndrome (CRS), neurotoxicity, graft rejection, on-target off-tumor toxicities, and tumor relapse have tied the rescuing hands of CAR T cell therapies. Moreover, in the case of solid tumor treatment, CAR T cell therapies have not yielded encouraging results mainly due to challenges such as the formidable network of the tumor microenvironments (TME) that operates in a suppressive fashion resulting in CAR T cell dysfunction. In this review, we tend to shine a light on emerging strategies and solutions for addressing the mentioned barriers. These solutions might dramatically help shorten the gap between a successful clinical outcome and the hope for it. Frontiers Media S.A. 2021-04-01 /pmc/articles/PMC8047470/ /pubmed/33869011 http://dx.doi.org/10.3389/fonc.2021.627549 Text en Copyright © 2021 Safarzadeh Kozani, Safarzadeh Kozani, Rahbarizadeh and Khoshtinat Nikkhoi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Safarzadeh Kozani, Pooria
Safarzadeh Kozani, Pouya
Rahbarizadeh, Fatemeh
Khoshtinat Nikkhoi, Shahryar
Strategies for Dodging the Obstacles in CAR T Cell Therapy
title Strategies for Dodging the Obstacles in CAR T Cell Therapy
title_full Strategies for Dodging the Obstacles in CAR T Cell Therapy
title_fullStr Strategies for Dodging the Obstacles in CAR T Cell Therapy
title_full_unstemmed Strategies for Dodging the Obstacles in CAR T Cell Therapy
title_short Strategies for Dodging the Obstacles in CAR T Cell Therapy
title_sort strategies for dodging the obstacles in car t cell therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047470/
https://www.ncbi.nlm.nih.gov/pubmed/33869011
http://dx.doi.org/10.3389/fonc.2021.627549
work_keys_str_mv AT safarzadehkozanipooria strategiesfordodgingtheobstaclesincartcelltherapy
AT safarzadehkozanipouya strategiesfordodgingtheobstaclesincartcelltherapy
AT rahbarizadehfatemeh strategiesfordodgingtheobstaclesincartcelltherapy
AT khoshtinatnikkhoishahryar strategiesfordodgingtheobstaclesincartcelltherapy